Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 10 May 24 424B3 Prospectus supplement
- 8 May 24 424B3 Prospectus supplement
- 4 Apr 24 EFFECT Notice of effectiveness
- 29 Mar 24 POS AM Prospectus update (post-effective amendment)
- 8 Mar 24 424B3 Prospectus supplement
- 6 Mar 24 424B4 Prospectus supplement with pricing info
- 4 Mar 24 424B3 Prospectus supplement
- 15 Feb 24 EFFECT Notice of effectiveness
-
13 Feb 24 S-1/A IPO registration (amended)
- 13 Feb 24 UPLOAD Letter from SEC
- 12 Feb 24 S-1 IPO registration
QNRX similar filings
Filing view
External links
Exhibit 23.1
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the inclusion in this Registration Statement of Quoin Pharmaceuticals, Ltd. on Amendment No. 1 to Form S-1 (File No. 333-277016) of our report dated March 15, 2023, except for Note 18, as to which the date is February 12, 2024, with respect to our audit of the consolidated financial statements of Quoin Pharmaceuticals, Ltd. as of and for the year ended December 31, 2022, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading “Experts” in such Prospectus.
| |
/s/ Marcum LLP | |
| |
Marcum LLP | |
East Hanover, New Jersey | |
February 13, 2024 | |